Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
CCT301-038
i
Other names:
CCT301-038, CCT301-38, CCT3-AXL-0038, CCT301038, CCT301 038, CCT30138, CCT3AXL0038, CCT301 38, CCT3 AXL 0038
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Exuma Biotech, Sunterra Biotech
Drug class:
AXL-targeted CAR-T immunotherapy
Related drugs:
‹
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)
›
Associations
News
Trials
Filter by
Latest
25d
Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma (clinicaltrials.gov)
P1/2, N=66, Terminated, Shanghai PerHum Therapeutics Co., Ltd. | Active, not recruiting --> Terminated; Adjustment of study strategy
25 days ago
Trial termination • Metastases
|
AXL (AXL Receptor Tyrosine Kinase) • ROR2 (Receptor Tyrosine Kinase Like Orphan Receptor 2)
|
cyclophosphamide • CCT301-038 • CCT301-59
25d
CCT301-38 CAR-T in Patients With Relapsed or Refractory AXL Positive Sarcomas (clinicaltrials.gov)
P1, N=9, Terminated, Shanghai PerHum Therapeutics Co., Ltd. | Trial completion date: Aug 2025 --> Oct 2024 | Recruiting --> Terminated; Adjustment of study strategy
25 days ago
Trial completion date • Trial termination
|
AXL (AXL Receptor Tyrosine Kinase)
|
AXL positive
|
cyclophosphamide • CCT301-038
over1year
CCT301-38 CAR-T in Patients With Relapsed or Refractory AXL Positive Sarcomas (clinicaltrials.gov)
P1, N=9, Recruiting, Shanghai PerHum Therapeutics Co., Ltd. | Trial completion date: Dec 2023 --> Aug 2025 | Trial primary completion date: Feb 2023 --> Aug 2024
over 1 year ago
Trial completion date • Trial primary completion date
|
AXL (AXL Receptor Tyrosine Kinase)
|
AXL positive
|
cyclophosphamide • CCT301-038
over2years
CCT301-38 CAR-T in Patients With Relapsed or Refractory AXL Positive Sarcomas (clinicaltrials.gov)
P1, N=9, Recruiting, Shanghai PerHum Therapeutics Co., Ltd. | Trial completion date: Jul 2023 --> Dec 2023 | Trial primary completion date: Aug 2022 --> Feb 2023
over 2 years ago
Trial completion date • Trial primary completion date
|
AXL (AXL Receptor Tyrosine Kinase)
|
AXL positive
|
cyclophosphamide • CCT301-038
3years
CCT301-38 CAR-T in Patients With Relapsed or Refractory AXL Positive Sarcomas (clinicaltrials.gov)
P1, N=9, Recruiting, Shanghai PerHum Therapeutics Co., Ltd.
3 years ago
Clinical • New P1 trial
|
AXL (AXL Receptor Tyrosine Kinase)
|
AXL positive
|
CCT301-038
3years
Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma (clinicaltrials.gov)
P1/2, N=66, Active, not recruiting, Shanghai PerHum Therapeutics Co., Ltd. | Trial completion date: Mar 2035 --> Jun 2023 | Trial primary completion date: Jan 2021 --> Jun 2022
3 years ago
Clinical • Trial completion date • Trial primary completion date
|
AXL (AXL Receptor Tyrosine Kinase) • ROR2 (Receptor Tyrosine Kinase Like Orphan Receptor 2)
|
CCT301-038 • CCT301-59
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login